Literature DB >> 29227878

Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.

Tamar Kikvidze1, Niklas Luhmann2, Elisabeth Avril2, Maia Butsashvili3, Konstantine Labartkava4, Aurélie Etienne2, Diane Le Pluart2, Ina Inaridze1, Ana Gamezardashvili3, David Kharshiladze1, Julie Bouscaillou5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29227878     DOI： 10.1016/j.drugpo.2017.11.014

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN： 0955-3959


× No keyword cloud information.
  7 in total

1.  Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention.

Authors:  Helen R Stagg; Julian Surey; Marie Francis; Jennifer MacLellan; Graham R Foster; André Charlett; Ibrahim Abubakar
Journal:  BMC Med       Date:  2019-04-01       Impact factor: 8.775

2.  On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.

Authors:  Ivdity Chikovani; Danielle C Ompad; Maia Uchaneishvili; Lela Sulaberidze; Ketevan Sikharulidze; Holly Hagan; Nancy L Van Devanter
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

Review 3.  Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.

Authors:  Sophia E Schröeder; Alisa Pedrana; Nick Scott; David Wilson; Christian Kuschel; Lisa Aufegger; Rifat Atun; Ricardo Baptista-Leite; Maia Butsashvili; Manal El-Sayed; Aneley Getahun; Saeed Hamid; Radi Hammad; Ellen 't Hoen; Sharon J Hutchinson; Jeffrey V Lazarus; Olufunmilayo Lesi; Wangsheng Li; Rosmawati Binti Mohamed; Sigurdur Olafsson; Raquel Peck; Annette H Sohn; Mark Sonderup; Catherine W Spearman; Tracy Swan; Mark Thursz; Tim Walker; Margaret Hellard; Jessica Howell
Journal:  Liver Int       Date:  2019-09-04       Impact factor: 5.828

4.  Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.

Authors:  Maia Butsashvili; Tinatin Abzianidze; George Kamkamidze; Lasha Gulbiani; Lia Gvinjilia; Tinatin Kuchuloria; Irina Tskhomelidze; Maka Gogia; Maia Tsereteli; Veronique Miollany; Tamar Kikvidze; Shaun Shadaker; Muazzam Nasrullah; Francisco Averhoff
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-03-28

5.  An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.

Authors:  Nyashadzaishe Mafirakureva; Jack Stone; Hannah Fraser; Yvonne Nzomukunda; Aron Maina; Angela W Thiong'o; Kibango Walter Kizito; Esther W K Mucara; C Inés González Diaz; Helgar Musyoki; Bernard Mundia; Peter Cherutich; Mercy Nyakowa; John Lizcano; Nok Chhun; Ann Kurth; Matthew J Akiyama; Wanjiru Waruiru; Parinita Bhattacharjee; Charles Cleland; Dmytro Donchuk; Niklas Luhmann; Anne Loarec; David Maman; Josephine Walker; Peter Vickerman
Journal:  Addiction       Date:  2021-07-28       Impact factor: 6.526

6.  Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis.

Authors:  Ximena A Levander; Taylor A Vega; Andrew Seaman; P Todd Korthuis; Honora Englander
Journal:  Subst Abus       Date:  2021-06-23       Impact factor: 3.716

Review 7.  Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review.

Authors:  Moaz Abdelwadoud; T Joseph Mattingly; Hemanuel Arroyo Seguí; Emily F Gorman; Eleanor M Perfetto
Journal:  Patient       Date:  2020-12-29       Impact factor: 3.883
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.